Sumitomo Pharma Co.

4506.TSE

9.21 USD

-0.23

-2.44%

Overview

Last close

9.21 usd

Market cap

3.66B usd

52 week high

9.44 usd

52 week low

1.81 usd

Target price

6.86 usd

Valuation

P/E

23.0963

Forward P/E

20.202

Price/Sales

1.3117

Price/Book Value

3.1335

Enterprise Value

5.63B usd

EV/Revenue

2.0689

EV/EBITDA

14.5598

Key financials

Revenue TTM

2.84B usd

Gross Profit TTM

1.73B usd

EBITDA TTM

416.56M usd

Earnings per Share

0.41 usd

Dividend

N/A usd

Total assets

4.98B usd

Net debt

1.89B usd

About

Sumitomo Pharma Co., Ltd. engages in manufacture, and purchase and sale of pharmaceutical products for medical treatment in Japan, North America, and Asia. The company offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. It also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. Further, the company offers veterinary drugs, medical devices, etc. It has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.